← Eichor
Condition: Signal Transduction Pathway Deregulation Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Signal Transduction Pathway Deregulation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06363734Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
Phase 2/Phase 3 · 6 location(s) · Gynaecologisch Oncologisch Centrum Zuid · NCT03458221
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.